CGD Policy Blogs
How Will PEPFAR Reach 4 Million AIDS Patients on Treatment by 2014: Expanded Access or Earlier Recruitment? Millions of Years of Life Hang in the Balance
On December 1 the White House announced a new five-year strategy for PEPFAR which aims to increase the number of patients PEPFAR directly supports on antiretroviral therapy from the current 2.4 million to 4 million by 2014.
WHO and UNAIDS have just put poor country AIDS treatment program managers on the spot. Will they choose to follow the new WHO advice to push patients to begin treatment earlier – when many are still healthy? Or will they turn their backs on the new advice and push instead for expanded access to those in need.
Will the New White House Initiative for Rigorous Evaluation Elicit a Response from the U.S. Foreign Assistance Agencies?
This October 7 memo from Peter Orszag is interesting not only for its emphasis on evaluation, but also for its use of a carrot approach instead of (in addition to?) a stick approach to getting the participation of the various agencies and bureaus of the US government. (Thanks to Mattias Lundberg for flagging this memo for me.)
This is a joint post with Josh Busby
Our research on the political economy of antiretrovirals (ARVs) is motivated by a key puzzle: why were AIDS activists and AIDS policy entrepreneurs successful in putting universal access to treatment on the international agenda when so many other global campaigns--whether in health care or other issue areas like climate change--have either failed or struggled to have much impact. In our paper, we make the case that the market for ARVs was politically constructed, meaning that activists had to bring the demand and supply sides of the market together through a variety of tactics and strategies (Tim Bartley makes a similar argument on forest certification schemes).
It’s entirely possible that the Obama administration will institute better global health policies than its predecessor, and appear to get worse results. This paradox, although painful, is all too easy to imagine.
Each year in Sub-Saharan Africa there are about 2-million new cases of HIV infection, most of whom would not need antiretroviral therapy (ART) under current guidelines for 8 to 12 more years. Since donors have not managed to place on treatment more than about half of those needing it each year, the 8 to 12 year lag between infection and need for treatment has been seen as a breathing space.
Task-Shifting Can Be Part of the Answer to ART Access—If the Numbers of Lower Level Health Workers Expand Fast Enough
There has been a great deal of discussion at this week’s IAS Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa of four expensive directions for proposed expansion of access to antiretroviral treatment for AIDS patients in poor countries (ART):
Today, as the Washington Post reports that Congress is suspending consideration of health reform for its August recess, it is a good time for those of us interested in following the issues to catch up with where the reform is going. Slate Magazine’s Online Guide to health reform is a great link to add to your favorites if you want to stay abreast of the discussion.
A study by Nirmala Ravishankar and colleagues at Chris Murray’s Institute for Health Metrics and Evaluation (IHME) published today in the Lancet and reported at Forbes and MSNBC gives the most comprehensive estimates yet available of the total amount that people in higher income countries have been spending to t